logo

For the Inventor, By the Inventor

Ghent, Belgium

Orionis Biosciences Bv

Calculating rank
USPTO Granted Patents = 25


Forward Citations = 37

Loading Chart...
Loading Chart...

10 inventors (with patents filed for the assignee):

goldMedal Nikolai Kley (25 out of 34 patents)

silverMedal Jan Tavernier (24 out of 73 patents)

bronzeMedal Lennart Zabeau (14 out of 20 patents)

4.  Erik Depla (10 out of 10 patents)

5.  Anje Cauwels (7 out of 12 patents)

6.  Sarah Gerlo (4 out of 8 patents)

7.  Frank Peelman (3 out of 14 patents)

8.  Leander Huyghe (2 out of 4 patents)

9.  Sandra Van Lint (1 out of 1 patent)

10.  Thomas Wueest (1 out of 1 patent)

11.  Nikolai Kley (0 patent)


Core Competencies:
Fibroblast Activation Protein
Interferon Alpha
Interferon Gamma
Chimeric Proteins
Clec9A Binding Agents
PD-1 Binding Agents
CD8 Binding Agents
Bi-functional Proteins
Therapeutic Targeting
Mutant Interferons
Signaling Agents

25 patents:

1. 12583941 - Fibroblast activation protein binding agents and use thereof (2026-03-24),
2. 12583898 - THERAPEUTIC INTERFERON ALPHA 1 PROTEINS (2026-03-24),
3. 12522641 - Targeted mutant interferon-gamma and uses thereof (2026-01-13),
4. 12473338 - TARGETED ENGINEERED INTERFERON AND USES THEREOF (2025-11-18),
5. 12453770 - CLEC9A binding agents (2025-10-28),
6. 12448447 - CD8 binding agents (2025-10-21),
7. 12410225 - Modulation of dendritic cell lineages (2025-09-09),
8. 12364753 - CD8 binding agents (2025-07-22),
9. 12351633 - PD-1 and PD-L1 binding agents (2025-07-08),
10. 12351614 - CLEC9A-based chimeric protein complexes (2025-07-08),
11. 12091463 - Clec9A binding agents comprising a recombinant heavy-chain only antibody (VHH) (2024-09-17),
12. 12084497 - SIRP1α targeted chimeric proteins and uses thereof (2024-09-10),
13. 11753463 - Therapeutic targeting of non-cellular structures (2023-09-12),
14. 11702477 - Bi-functional chimeric proteins and uses thereof (2023-07-18),
15. 11661455 - Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety (2023-05-30),
Company Overview
Orionis Biosciences Bv, based in Ghent, Belgium, is a biotechnology company focused on the development of innovative therapeutic solutions. The organization specializes in harnessing advanced biological research to create novel treatments, particularly in the fields of oncology and immunology. By leveraging cutting-edge technologies and a deep understanding of disease mechanisms, Orionis aims to address unmet medical needs and improve patient outcomes through its research-driven approach.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

25 Patents

#9 in Ghent

#134 in Belgium

#25,730 in the World

Ghent, BE
Ghent, Belgium

Orionis Biosciences Bv

Forward Citations = 37

10 inventors:

goldMedal Nikolai Kley (25 out of 34 patents)

silverMedal Jan Tavernier (24 out of 73 patents)

bronzeMedal Lennart Zabeau (14 out of 20 patents)

4.  Erik Depla (10 out of 10 patents)

5.  Anje Cauwels (7 out of 12 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Orionis Biosciences Bv. Retrieved from https://idiyas.com/company/orionis-biosciences-bv

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…